ABSTRACT
Purpose: The purpose of this study was to evaluate the effectiveness of the CLUE protocol in COVID-19 triage. Materials and Methods: Patients who presented to the emergency department due to dyspnea with oxygen saturation below 95 % and were diagnosed with COVID-19 by reverse transcription polymerase chain reaction (RTPCR) tests were included in this prospective, observational study. Patients included in the study underwent lung ultrasound (LUS) in the light of the CLUE protocol, and were accordingly given LUS scores of between 0 and 36, also within the scope of the protocol. Patients were placed under observation, and clinical outcomes of discharge from the emergency department, admission to the ward, and admission to intensive care or discharge were recorded. ROC analysis was applied in the calculation of threshold values for LUS scores predicting discharge, admission to intensive care, and mortality. Results: Forty-five patients with a mean age of 63 +/- 18 years were included in the study. Fifteen patients (33 %) were treated on an outpatient basis and discharged, while 12 (27 %) were admitted to the ward and 18 (40 %) to the intensive care unit. Mortality occurred in 15 (33 %) patients. An LUS score lower than 3 was 97 % sensitive and 80 % specific for discharge, a score greater than 10 was 94 sensitive and 78 % specific for admission to the intensive care unit, and a score higher than 11 was 93 % sensitive and 87 % specific for mortality. Based on regression analysis, an LUS score higher than 10 emerged as an independent risk factor for intensive care requirement, a score lower than 3 for discharge, and a score over 11 for mortality. Conclusion: The CLUE protocol may be a useful bedside test in COVID-19 triage, and one that does not involve radiation or require laboratory tests.
ABSTRACT
Aim: The neuroinflammatory hypothesis suggests that proinflammatory cytokines or the immune system may play a role in the etiopathogenesis of depression. COVID-19 affects older people the most because their immune systems are weakened. In this study, we aimed to examine the effect of using antidepressant use on mortality in patients infected with COVID-19. Material and Methods: Our study was developed as a retrospective examination of unique central patient records. In our study, the diagnosis of COVID-19 diagnostics (U07.3) was between the ICD-10 classification (U07.3) and the diagnosis of depressive emotional state disorders (F31, F32, F33, F34) and patients with the diagnosis of COVID 19 confirmed by the test result were included. Results: Considering the relationship between the use of antidepressants and mortality in COVID-19 patients, it was seen that the mortality rate was significantly lower in those using antidepressants (p <0.05). The presence of chronic disease was found to be significantly associated with mortality in COVID-19. The mortality rates of patients with chronic diseases were found to be higher (p <0.01). Discussion: In our study, we found that antidepressants did not have any superiority over each other in terms of mortality in COVID-19 patients.However, when all anti depressants were evaluated in our study, we observed that drug use had a positive effect on statistically significant mortality (p <0.05). More enlightening results will emerge in larger case series.